5751-17-7

Usage

Type of compound

pyrimidinone derivative

Contains

methylsulfanyl group, propyl group

Use

building block for the synthesis of various drugs and bioactive molecules in the pharmaceutical industry

Potential applications

development of new pharmacological agents

Possesses

structural features and reactivity, biological activities and properties

Further research needed

to fully understand its potential uses and applications.

Upstream product

• 51-52-5 propylthiouracil 
• 74-88-4 methyl iodide 
• 3249-68-1 ethyl butyroyl acetate 
• 51-52-5 propylthiouracil 
• 51-52-5 2-mercapto-6-propyl-pyrimidin-4-ol 
• 512-56-1 trimethyl phosphite 

Downstream Products

• 1394805-32-3 (R)-N-{1-[2-(3-cyano-4-methylphenylamino)-6-propylpyrimidin-4-yl]piperidin-3-yl}acetamide hydrochloride 
• 1394851-74-1 N₄,N₄-diethyl-N₂-(4-fluorophenyl)-6-propylpyrimidine-2,4-diamine hydrochloride 
• 1394851-65-0 N₄,N₄-diethyl-N₂-(4-fluorophenyl)-6-propylpyrimidine-2,4-diamine 
• 1394805-35-6 (R)-3-{4-[3-(propylamino)piperidin-1-yl]-6-propylpyrimidin-2-ylamino}benzonitrile 
• 1394806-90-6 (R)-3-[4-(3-aminopiperidin-1-yl)-6-propylpyrimidin-2-ylamino]benzonitrile 
• 1394804-66-0 (R)-5-[4-(3-aminopiperidin-1-yl)-6-propylpyrimidin-2-ylamino]-2-methylbenzonitrile 
• 1394803-00-9 N-(4-fluorophenyl)-4-(piperidin-1-yl)-6-propylpyrimidin-2-amine 
• 1394321-95-9 4-chloro-N-[4-fluoro-3-(trifluoromethyl)phenyl]-6-propylpyrimidin-2-amine 
• 1241672-72-9 4-chloro-N-(4-fluorophenyl)-6-propylpyrimidin-2-amine 

Relevant academic research and scientific papers

Molecular Recognition of Creatinine

A host-guest system involving derivatives of 2-amino-4(3H)-pyrimidone and creatinine was developed. 1H NMR and 13C NMR experiments give evidence of complex formation.A geometry optimazation with Gaussian 88 suggests a complex structure in which the 5-membered and the 6-membered heteroring are connected by one long and two shorter hydrogen bonds.The hosts described strongly enhance the extraction of creatinine from its aqueous solution into CH2Cl2 and CDCl3.As the creatinine concentration in the organic solvents may be determined by measuring the changes in the UV spectrum of the hosts upon complexation, derivatives of 2-amino-4(3H)-pyrimidone may eventually be used in optical creatinine sensors.

A Mild Heteroatom (O -, N -, and S -) Methylation Protocol Using Trimethyl Phosphate (TMP)-Ca(OH) 2Combination

A mild heteroatom methylation protocol using trimethyl phosphate (TMP)-Ca(OH)2combination has been developed, which proceeds in DMF, or water, or under neat conditions, at 80 °C or at room temperature. A series of O-, N-, and S-nucleophiles, including phenols, sulfonamides, N-heterocycles, such as 9H-carbazole, indole derivatives, and 1,8-naphthalimide, and aryl/alkyl thiols, are suitable substrates for this protocol. The high efficiency, operational simplicity, scalability, cost-efficiency, and environmentally friendly nature of this protocol make it an attractive alternative to the conventional base-promoted heteroatom methylation procedures.

DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF

The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.

DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF

The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.

DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF

The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.

DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF

The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.

ANTIVIRAL PYRIMIDINES

Disclosed herein are novel compounds comprising substituted pyrimidines, pyrazolopyrimtdines, and imidazolopyrimidines, the syntheses thereof, and compositions thereof, including pharmaceutical compositions, comprising the novel pyrimidines, pyrazolopyrimtdines, imidazolpyrimidines and related compounds. Such compounds function to inhibit entry of viruses of the Flaviviridae family, including Hepatitis C virus (HCV), into cells that are susceptible to virus infection. These compounds are useful for the treatment, therapy and/or prophylaxis of viral diseases and infection, including HCV infection.

Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors

Morphing structural features of HTS-derived chemotypes led to the discovery of novel 2-cyano-pyrimidine inhibitors of cathepsin K with good pharmacokinetic profiles, for example, compound 20 showed high catK potency (IC50 = 4 nM), >580-fold selectivity over catL and catB, and oral bioavailability in the rat of 52%.

Synthesis of 2-bromomethyl-3-hydroxy-2-hydroxymethyl-propyl pyrimidine and theophylline nucleosides under microwave irradiation. Evaluation of their activity against hepatitis B virus

Alkylation of 2-methylthiopyrimidin-4(1H)-one (1a) and its 5(6)-alkyl derivatives 1b - d as well as theophylline (7) with 2,2- bis (bromomethyl)-1,3-diacetoxypropane (2) under microwave irradia-tion gave the corresponding acyclonucleosides 1-[(3-acetoxy-2-acetoxymethyl-2-bromomethyl) prop-1- yl ]-2-methyl-thio pyrmidin-4(1H)-ones 3a - d and 7-[(3-acetoxy-2- acetoxymethyl-2-bromomethyl)prop-1- yl]theophylline (8), which upon further irradiation gave the double-headed acyclonucleosides 1,1 ′-[(2,2- diacetoxymethyl)-1,3-propylidene]- bis [(2-(methylthio)-pyrimidin-4(1H)-ones] 4a - c , and 7,7 ′-[(2,2-diacetoxymethyl)-1,3-propylidene]- bis (theophylline) (9). The deacetylated derivatives were obtained by the action of sodium methoxide. The activity of deacetylated nucleosides against Hepatitis B virus was evaluated. Compound 5b showed moderate inhibition activity against HBV with mild cytotoxicity. Copyright Taylor & Francis Group, LLC.

4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES

The invention relates to 4-phenyl-pyrimidine-2-carbonitrile derivatives having the general formula (I) or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives as well as to the use thereof in the preparation of a medicament suitable for the treatment of osteoporosis, atherosclerosis, inflammation and immune disorders, such as rheumatoid arthritis, and chronic pain, such as neuropathic pain.